SK Bioscience Co Ltd
KRX:302440
SK Bioscience Co Ltd
Free Cash Flow
SK Bioscience Co Ltd
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Free Cash Flow
-₩300.2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Free Cash Flow
₩568.3B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
25%
|
CAGR 10-Years
50%
|
|
|
H
|
Hugel Inc
KOSDAQ:145020
|
Free Cash Flow
₩115.7B
|
CAGR 3-Years
46%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
|
N
|
NatureCell Co Ltd
KOSDAQ:007390
|
Free Cash Flow
-₩1.6B
|
CAGR 3-Years
47%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-24%
|
|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
Free Cash Flow
₩101.2B
|
CAGR 3-Years
34%
|
CAGR 5-Years
61%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Free Cash Flow
₩28.6B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
104%
|
CAGR 10-Years
38%
|
|
SK Bioscience Co Ltd
Glance View
SK Bioscience Co Ltd., a remarkable enterprise carved out of the South Korean corporate landscape, operates at the dynamic intersection of biotechnology and pharmaceuticals. A part of the larger SK Group, one of Korea's leading conglomerates, the company was officially established in 2018 from SK Chemicals' life sciences division. Its primary focus is on developing and manufacturing vaccines, serving both public health needs locally and globally. The company has swiftly gained prominence for its role in the COVID-19 pandemic, particularly with the production of vaccines in collaboration with significant players such as AstraZeneca and Novavax. This strategic engagement loop has positioned SK Bioscience not only as a critical player in health crises management but also as a pivotal contributor to global health security. At the heart of SK Bioscience's business model is its ability to leverage cutting-edge research and robust manufacturing capabilities. The firm generates revenue through various channels, including product sales of its vaccines and other pharmaceuticals, contract manufacturing services, and partnerships with global entities, allowing it a diversified income stream. Its adeptness in innovation, underpinned by a strong R&D framework, ensures a steady development pipeline, supporting long-term growth ambitions. Through these strategic activities, SK Bioscience aligns itself with the SK Group’s broader commitment to social value and environmental, social, and governance (ESG) principles, fortifying its reputation as a company that not only seeks financial success but also endeavors to wield a positive global impact.
See Also
What is SK Bioscience Co Ltd's Free Cash Flow?
Free Cash Flow
-300.2B
KRW
Based on the financial report for Dec 31, 2024, SK Bioscience Co Ltd's Free Cash Flow amounts to -300.2B KRW.
What is SK Bioscience Co Ltd's Free Cash Flow growth rate?
Free Cash Flow CAGR 1Y
-1 333%
Over the last year, the Free Cash Flow growth was -1 333%.
You don't have any saved screeners yet